These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2655907)

  • 1. Fenofibrate for the treatment of type IV and V hyperlipoproteinemias: a double-blind, placebo-controlled multicenter US study.
    Goldberg AC; Schonfeld G; Feldman EB; Ginsberg HN; Hunninghake DB; Insull W; Knopp RH; Kwiterovich PO; Mellies MJ; Pickering J
    Clin Ther; 1989; 11(1):69-83. PubMed ID: 2655907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate in type IV and type V hyperlipoproteinemia.
    Seidehamel RJ
    Cardiology; 1989; 76 Suppl 1():23-8; discussion 29-32. PubMed ID: 2653622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia.
    Farnier M; Bonnefous F; Debbas N; Irvine A
    Arch Intern Med; 1994 Feb; 154(4):441-9. PubMed ID: 8117177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible increase of the apo CII/apo CIII-1 ratio in the very low density lipoproteins after procetofen treatment in hypertriglyceridemic patients.
    Franceschini G; Sirtori M; Gianfranceschi G; Frosi T; Montanari G; Sirtori CR
    Artery; 1985; 12(6):363-81. PubMed ID: 4051756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
    Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].
    Schiffl H; Weidmann P; Fragiacomo C; Noseda G; Bachmann C
    Schweiz Med Wochenschr; 1985 Jun; 115(26):907-11. PubMed ID: 3927481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia.
    Krempf M; Rohmer V; Farnier M; Issa-Sayegh M; Corda C; Sirugue I; Gerlinger C; Masseyeff-Elbaz MF
    Diabetes Metab; 2000 May; 26(3):184-91. PubMed ID: 10880891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinico-biochemical activity and tolerance of the hypolipidemic preparation lipanthyl].
    Ol'binskaia LI; Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
    Ter Arkh; 1991; 63(8):61-4. PubMed ID: 1792621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison of the hypolipemic effects of bezafibrate and fenofibrate in patients with hyperlipoproteinemia type II and IV].
    Sznajderman M
    Przegl Lek; 1984; 41(7):493-9. PubMed ID: 6390536
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
    Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
    Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S
    Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fenofibrate: hypolipaemic activity and safety in long-term treatment. Effects on HDL, LDL, VLDL and apoprotein B in short-term treatment (author's transl)].
    Rouffy J; Sauvanet JP; Chanu B; Bakir R; Goy-Loeper J; Saya C; Pinaroli F
    Nouv Presse Med; 1980 Dec; 9(49):3747-51. PubMed ID: 7208341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.
    LaRosa JC; Miller VT; Edwards KD; DeBovis MR; Stoy DB
    Artery; 1987; 14(6):338-50. PubMed ID: 3314798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

  • 18. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins A and B in type IIa HLP (author's transl)].
    Micheli H; Pometta D; Gustafson A
    Nouv Presse Med; 1980 Dec; 9(49):3759-62. PubMed ID: 7208343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.